Wanbury Ltd (WANBURY) is currently trading at 243.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Wanbury Limited specializes in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs) and formulations. It holds a significant global market share in products such as Metformin and Sertraline, establishing robust leadership in these key therapeutic categories. The company has successfully undergone an operational and financial turnaround over the last two years, transitioning towards growth momentum and de-risked financial structures, with a notable reduction in debt levels and borrowing costs. Wanbury has fortified its market presence with established global regulatory approvals, including USFDA and ANVISA, enhancing its credibility and access to developed markets. Recent advances in the API business include the launch of new anaesthetic drugs and plans for 4 new molecule commercializations annually, focusing on high-value and large-volume market opportunities. The company's business strategy emphasizes building its formulations and API brands, focusing on new therapeutic launches and geographic expansion, while deploying digital transformations for enhanced operational efficiencies.

Over the past 52 weeks, Wanbury Ltd has traded between a low of ₹162.00 and a high of ₹330.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Wanbury Ltd has a market capitalization of approximately 883.97. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Wanbury Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.48 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 883.97 Cr, Wanbury Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Wanbury Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Wanbury Ltd is 20.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.